Herpes Zoster Market Share

North America Market Analysis

North America in herpes zoster market is anticipated to hold more than 55.4% revenue share by 2037. The well-established healthcare infrastructure of this region is driving growth in this sector. The rising prevalence rate of VZV infection has forced regional authorities to focus on implementing preventive and curative measures in all healthcare institutions to ensure accessibility. According to the CDC report, published in June 2024, around 99.5% population born before 1980 in the U.S. is infected with wild type varicella-zoster virus. The report further stated that nearly 1 in 3 people in the country are poised to suffer from herpes zoster at least once in their lifetime.

Weakness of immunity found in a majority of the population of the U.S. has forced the country’s public health associations to take initiatives in promoting and penetrating preventive solutions such as vaccination. This is further inspiring for them to invest and encourage more research projects, propelling growth in its domestic herpes zoster market. For instance, in October 2023, NIH announced a USD 2.8 million fund to support Rational Vaccines’s R&D, developing new vaccines for and other treatment methods for HSV.

Canada is also proactively taking part in the herpes zoster market by strengthening its healthcare infrastructure to reduce the widespread infection across the region. The cautious impact of the virus on the country’s population is concerning the governing bodies and pushing them to adopt proven and tested treatments and preventive solutions. However, the lack of funding is impacting the vaccine access and development progress of this landscape. In this regard, the National Advisory Committee on Immunization in Canada has recommended to implement adult herpes vaccines.

APAC Market Statistics

The Asia Pacific landscape is expected to witness the fastest growth in the herpes zoster market by the end of 2037. Emerging economies such as China, India, and Japan are contributing to regional progress with increased expenditure on healthcare. The International Monetary Fund revealed in April 2024, that the GDP of APAC achieved a 5% increment in 2023. They are remarkably adopting innovative treatments and therapies to reduce the incidences and improve patient outcomes. Moreover, the integration of advanced technologies such as AI and cloud computing have highly influenced drug discoveries, revolutionizing their approach towards viral diseases.

India, with its strong emphasis on pharmaceutical progress, it has created a great business atmosphere for both domestic and global leaders in the herpes zoster market. According to an IBEF estimation, the pharma industry of India is projected to reach USD 130 billion by 2030. The country’s lucrative marketplace is now attracting foreign forces for investments and participation. For instance, in April 2023, GSK launched Shingrix in India to prevent shingles in adults, aging 50 years or over. The strategic expansion was aimed at setting its footprint in such a dynamic landscape.

China is significantly growing in the herpes zoster market with its efforts to make vaccines and medicines accessible and affordable for all citizens. As the economic burden of HSV treatments is a setback in this sector, the country is focusing on heightening the willingness to vaccinate among citizens. For instance, in October 2023, Rational Vaccines collaborated with Shenzhen Mellow Hope Pharm Industrial Co., Ltd. to develop, manufacture, and commercialize live vaccines against herpes simplex viruses in China. The joint R&D venture aimed at offering a prominent solution to serve the broad range of consumers in the country.